Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2011 10:03 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to File for Market Authorization to Sell Vitaros(R) for Erectile Dysfunction in Latin America

SAN DIEGO, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file for market authorization to sell its erectile dysfunction drug,...
August 04, 2011 13:19 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Provides Corporate Mid-Year Update

SAN DIEGO, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today a corporate mid-year update covering...
July 19, 2011 09:57 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Files Marketing Application for Vitaros(R) as a Treatment for Erectile Dysfunction in Switzerland

SAN DIEGO, July 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today its filing of a marketing application for Vitaros® as a treatment for patients...
July 06, 2011 09:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Sells Bio-Quant CRO Subsidiary to BioTox Sciences

SAN DIEGO, July 6, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has sold its wholly-owned subsidiary, Bio-Quant, Inc. ("Bio-Quant"), a...
June 28, 2011 10:47 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences' Marketing Application for Vitaros(R), for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe

SAN DIEGO, June 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that its marketing application for Vitaros®, indicated for the treatment of...
June 27, 2011 10:17 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa(TM) Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus

SAN DIEGO, June 27, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that, based on a successful and statistically significant reanalysis of its U.S....
June 24, 2011 10:33 ET | Source: Seelos Therapeutics, Inc.

Apricus Bio CEO Bassam Damaj to Present at the 2011 Biotechnology Industry Organization (BIO) International Convention

SAN DIEGO, June 24, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) Chairman, President and Chief Executive Officer, Dr. Bassam Damaj, will...
June 17, 2011 14:25 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra(R) Litigation is Successful

SAN DIEGO, June 17, 2011 (GLOBE NEWSWIRE) -- Dr. Bassam Damaj, the Chairman, President and Chief Executive Officer of Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI)...
June 14, 2011 09:47 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Added to Russell Microcap Index

SAN DIEGO, June 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the San Diego pharmaceutical company, which...
June 03, 2011 10:17 ET | Source: Seelos Therapeutics, Inc.

Apricus Bio CEO to Present Commercialization Plans for Vitaros(R) at Jefferies 2011 Global Healthcare Conference

SAN DIEGO, June 3, 2011 (GLOBE NEWSWIRE) -- Bassam Damaj, PhD., Chief Executive Officer of Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that he...